Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 3, 2026

Zacks.com featured highlights include Columbia Sportswear, Etsy, HubSpot and Roku

View original at finance.yahoo.com
Zacks.com featured highlights include Columbia Sportswear, Etsy, HubSpot and Roku For Immediate Release Chicago, IL – March 3, 2026 – Stocks in this week’s article are Columbia Sportswear Co…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Marketplace GMS is projected to be between $2.38 billion and $2.43 billion for Q1 2026

    80% confidence
  • Full-year 2026 net revenues are projected to be $5.5 billion with a gross profit of $2.435 billion and adjusted EBITDA of $635 million

    80% confidence
  • While high liquidity can indicate that a company is efficiently managing its short-term obligations, it may also suggest underutilization of resources

    80% confidence
  • Zacks stock-picking system has more than doubled the market from 1988 through 2016 with an average gain of +25% per year

    80% confidence
  • Zacks.com is the #1 site for screening stocks

    80% confidence
  • For 2026, Roku expects platform revenues of $4.89 billion, implying 18% year-over-year growth, with gross margin expected to be between 51% and 52%

    80% confidence
  • For 2026, HubSpot management estimates revenues between $3.69 billion and $3.7 billion, up 18% year over year on a reported basis

    80% confidence
  • A balanced assessment of both liquidity and efficiency can help identify truly promising investment opportunities

    80% confidence
  • For 2026, Columbia Sportswear expects net sales to grow 1% to 3%, implying revenues of $3.43 billion to $3.5 billion

    80% confidence
  • For the first quarter of 2026, Etsy anticipates the take rate to be roughly 25.5%

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com